ClinicalTrials.gg
Drug

Pazopanib clinical trials

Also written Votrient, GW786034B and GW786034.

studies test it
212
open now
9
in phase 3
13
first study started
2002

How each study uses pazopanib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the pazopanib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
19 Oct 2009 · VOTRIENT · NDA 022465 (FDA, Drugs@FDA)
European Union
14 Jun 2010 · Votrient · EMEA/H/C/001141 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pazopanib
132
Pazopanib Hydrochloride
42
Pazopanib (GW786034)
10
Pazopater
4
pazopanib eye drops
2

Brand

Votrient
80

Development codes

GW786034B
32
GW786034
31
PZP034
1

In one entry with another drug

Given together, or one or the other

Pazopanib and Paclitaxel
2

Studies by the year they started

211 studies that test it; most in 2010 (36)

Studies that test pazopanib, by start year
YearStudies
20021
20041
20054
200612
200712
200814
200912
201036
201132
201227
201312
20147
201518
20165
20174
20182
20193
20232
20244
20252
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
65
Phase 2
142
Phase 3
13
Phase 4
4
No phase
7

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 55 · Other 157

GlaxoSmithKline (42) · National Cancer Institute (NCI) (24) · Novartis Pharmaceuticals (10) · M.D. Anderson Cancer Center (9) · Samsung Medical Center (8) · Washington University School of Medicine (4) · Northwestern University (3) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (3)

Often tested with

Tested in the same studies.

Everolimus (9) · Paclitaxel (9) · Gemcitabine (8) · Sunitinib (7) · Temsirolimus (5) · Lapatinib (5) · Doxorubicin (4) · Topotecan (4)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 3 phase 3 studies under way

Pazopanib is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 3

Studies that test pazopanib.

Studies

Open first, then newest update. How each study uses pazopanib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 212

See all 212 studies that test pazopanib →

Given beside what is tested · 24 — pazopanib is usual care or a partner of the new treatment

Showing 20 of 24.

As the comparator · 8 — what is tested is compared with pazopanib

Codes

What other systems call pazopanib · ClinicalTrials.gg INT005030

  • MeSH (NLM) C516667pazopanibConfirmed NLM, Wikidata
  • UNII (FDA) 7RN5DR86CKPAZOPANIBConfirmed FDA, NLM, Wikidata
  • RxNorm 714438Confirmed FDA, Wikidata
  • Wikidata Q7157043pazopanibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C74547PazopanibOne source FDA
  • DrugBank DB06589One source Wikidata

Also registered as pazopanib hydrochloride (UNII 33Y9ANM545 · RxNorm 732187).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.